Q-omics provides the consensus-scored C2CD4C profile across patient tissues and cancer cell-line models. C2CD4C expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, C2CD4C is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, C2CD4C protein abundance shows 14,152 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where C2CD4C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2CD4C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2CD4C survival associations across molecular data types. C2CD4C RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2CD4C RNA expression–survival associations across cancer types. High C2CD4C expression shows unfavorable associations in MESO, UVM, ACC and KIRP, but favorable associations in KIRC and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for C2CD4C RNA expression.
This table summarizes C2CD4C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for C2CD4C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2CD4C shows lower tumor expression in UCEC and BRCA and higher tumor expression in HNSC, KIRC, CHOL and THCA. The HNSC box plot shows higher C2CD4C RNA expression in tumor versus normal tissue (log2 FC = +0.953, t-test p < 0.001).
This table shows molecular features associated with C2CD4C in patient tissues and cancer cell lines. In patient samples, C2CD4C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, C2CD4C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
